[April 13, 2016] |
|
SCRA Portfolio Company KIYATEC Announces Inaugural Scientific Advisory Board Members
KIYATEC, a leader in emerging 3D ex vivo predictive cancer
diagnostics, today announced the appointment of leading experts to its
scientific advisory board (SAB). The SAB will serve in a strategic
oversight capacity to help guide KIYATEC as it continues the development
and validation of predictive cancer diagnostics and complex ex vivo
3D tumor models.
"This is the ideal group to help us take a quantum leap forward for
cancer patients and their treatment decisions," said Matt Gevaert,
Ph.D., KIYATEC's CEO. "The impressive scientific and clinical
backgrounds of our SAB members bring a level of expertise rarely seen in
the clinical diagnostics markets. In conjunction with our exceptional
scientific team at KIYATEC, our SAB will lead us towards developing the
world's most clinically relevant and predictive cancer diagnostics."
The members of KIYATEC's scientific advisory board include:
-
Carlos L. Arteaga, MD (Vanderbilt University) is the Donna S.
Hall Chair in Breast Cancer Research and Professor of Medicine and
Cancer Biology at Vanderbilt University. Dr. Arteaga is Director of
the Center for Cancer Targeted Therapies and the Breast Cancer Program
and Associate Director for Translational/Clinical Research at the
Vanderbilt-Ingram Cancer Center (VICC). He is funded by the National
Cancer Institute, the American Cancer Society, the Department of
Defense Breast Cancer Research Program and Stand Up 2 Cancer (SU2C)
among others. He is an inducted member of the American Society of
Clinical Investigation (1998) and the Association of American
Physicians (2005). Dr. Arteaga is a former recipient of the AACR
Richard & Hinda Rosenthal Award, an ACS (News - Alert) Clinical Research Professor
Award, the 2009 Gianni Bonadonna Award from the American Society of
Clinical Oncology (ASCO), the 2011 Brinker Award from the Susan G.
Komen for the Cure Foundation, and the 2015 Prize for Scientific
Excellence in Medicine from the American-Italian Cancer Foundation. He
was elected Fellow of the AACR Academy in 2015 and serves in the
Scientific Advisory Board of the Komen Foundation. He served as the
2014-5 President of the American Association of Cancer Research (AACR).
-
David Kaplan, PhD (Tufts University) is the Stern Family
Professor of Engineering, an Endowed Chair at Tufts Universiy. He is
also Professor and Chair of the Department of Biomedical Engineering
there and also holds faculty appointments in the School of Medicine,
the School of Dental Medicine, Department of Chemistry and the
Department of Chemical and Biological Engineering. His research focus
is on biopolymer engineering with emphasis on studies related to
biomaterials engineering and functional tissue
engineering/regenerative medicine. He has published over 600 peer
reviewed papers and edited eight books. He directs the NIH P41 Tissue
Engineering Resource Center (TERC) bridging Tufts University and
Columbia University and is Associate Editor for the ACS journal
Biomacromolecules. He has received a number of awards for teaching.
Dr. Kaplan is an Elected Fellow of the American Institute of Medical
and Biological Engineering, has been honored with the Columbus
Discovery Medal and Society for Biomaterials Clemson Award and serves
of the editorial boards of numerous scientific journals.
-
Anil Sood, MD (MD Anderson) is the Vice Chair for Translational
Research in the Departments of Gynecologic Oncology & Reproductive
Medicine at MD Anderson, and is a Leader in Breast and Ovarian Cancers
Moon Shot program focusing on triple-negative breast cancer (TNBC) and
high-grade serous ovarian cancer (HGSOC). He is also Director of the
Blanton-Davis Ovarian Cancer Research Program and Co-Director of the
Center for RNA Interference and Non-Coding RNA. Dr. Sood has received
major recognition for his research accomplishments including the
Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in
Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research
Prize for Outstanding Gynecologic Cancer Researcher. He is an elected
member of the American Society for Clinical Investigation and AAAS.
"The formation of KIYATEC's SAB reflects our collective commitment to
translate patient-derived tumor models into functional drug response
assays and biomarkers," said Hal Crosswell, MD, Chief Medical Officer of
KIYATEC. "We are honored to be working with such an esteemed and
accomplished board who share our mission of improving lives of cancer
patients."
KIYATEC has been a part of SCRA's SC Launch program since 2007. For more
information on KIYATEC visit http://www.kiyatec.com/.
ABOUT KIYATEC, INC.
KIYATEC prioritizes accurate ex vivo prediction of patients' response to
drug treatment, with a focus on data correlation to human clinical
outcomes. The company creates and utilizes live phenotypic 3D cell-based
models for drug response profiling. These models are applied in order to
generate information relevant to preclinical testing, clinical trials
and clinical diagnostics applications. By accurately predicting patient
drug response without ever exposing actual patients to drugs, KIYATEC
will create informed drug selection that minimizes clinical trials'
failures and maximizes patient outcomes in the clinic. For more
information, please visit www.kiyatec.com
or follow KIYATEC on Twitter (News - Alert) (@KIYATEC).
ABOUT SCRA
Chartered in 1983 by the state of South Carolina, SCRA enriches South
Carolina's technology economy. SCRA improves the development and growth
of South Carolina's innovation ecosystem by supporting entrepreneurs,
enabling university research commercialization and connecting industry
to innovators. For further information, visit http://www.scra.org/.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160413006145/en/
[ Back To TMCnet.com's Homepage ]
|